论文部分内容阅读
１９９３年１１月至１９９５年１月１８例小儿恶性肿瘤病人接受异环磷酰胺为主的化疗共３８个疗程，异环磷酰胺剂量为每次１．３～１．７ｇ／Ｍ２×５天，同时每天给予每克异环环磷酰胺１．２ｇ美斯纳及水化、碱化，结果表明异环磷酰胺在上述用法时较为安全，可以避免主要毒性反应一出血性膀胱炎，骨随抑制时间较为短暂，未发生致死性感染，无明显肝脏毒性作用。３～１２个月短期随访结果显示异环磷酰胺对Ｂ细胞型恶性淋巴瘤、神经母细胞瘤、横纹肌肉危及肾母细胞瘤有明显效果，并在环磷酰胺抗药时仍有效。
From November 1993 to January 1995, 18 patients with pediatric malignant tumors were treated with ifosfamide-based chemotherapy for a total of 38 courses of treatment, ifosfamide dose of 1.3 ~ 1.7g / M2 × 5 days, At the same time per day given 1.2g ifosfamide cyclophosphamide and hydration, alkalization, the results show that ifosfamide is more safe in the above usage, to avoid the main toxicity of a hemorrhagic cystitis, bone with inhibition Time is short, no fatal infection, no significant role in liver toxicity. Short-term follow-up of 3 to 12 months showed that ifosfamide had a significant effect on B-cell malignant lymphoma, neuroblastoma, and striated muscle at the risk of nephroblastoma, and remained effective at cyclophosphamide resistance.